HUTCHMED (China) Limited (HCM) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Hutchmed (china) Limited.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.051 -- 00:00:04.853 Welcome everyone. Thank you for joining Hachmed 00:00:04.853 -- 00:00:09.335 2026 interim results announcement and presentation. 00:00:09.335 -- 00:00:15.017 Before we start, I would just like to go over the safe harbors statement and disclaimer 00:00:15.017 -- 00:00:20.139 on page two. The performance and results of operation of Hachmed Group contained within 00:00:20.139 -- 00:00:25.441 this presentation are historical in nature and past performance is no guarantee 00:00:25.441 -- 00:00:27.722 of future results. 00:00:27.722 -- 00:00:33.304 Next, I would like to invite our Acting CEO and CFO, 00:00:33.304 -- 00:00:37.865 Johnny Chan, to start the opening. Johnny? 00:00:37.865 -- 00:00:43.286 Okay, thank you, David. And welcome everyone again, joining our interim results webcast 00:00:43.286 -- 00:00:44.807 tonight. 00:00:44.807 -- 00:00:50.428 Together with me, we have our Deputy CFO, Lorenzo Zhou, 00:00:50.428 -- 00:00:55.061 also our George Yuan, Head of Commercial and also our Dr. 00:00:55.061 -- 00:00:59.925 Dai, Head of Discovery and Global Portfolio Management. 00:00:59.925 -- 00:01:05.269 All of us will be sharing with you our first half results and outlook. 00:01:05.269 -- 00:01:10.533 So on page four, as you can all see, we have achieved a lot in the first half. 00:01:10.533 -- 00:01:15.937 China product sales have very strong results, especially Elinate and Solenda, 00:01:15.937 -- 00:01:19.060 which grew by over 40%. 00:01:19.060 -- 00:01:22.967 Fusecla global in-market sales were strong, 00:01:22.967 -- 00:01:28.848 Ex-US markets were up 70% after rapid geographic expansion. 00:01:28.848 -- 00:01:33.609 On the bottom left, we have received two approved label expansions. 00:01:33.609 -- 00:01:38.590 Fluquitinib for RCC...